A novel series of IKKβ inhibitors part I: Initial SAR studies of a HTS hit

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 1, 2011, Pages 417-422

  Cushing, Timothy D ^a   Baichwal, Vijay ^a   Berry, Karen ^a   Billedeau, Roland ^b   Bordunov, Viola ^b   Broka, Chris ^b   Cardozo, Mario ^a   Cheng, Peng ^a   Clark, David ^a   Dalrymple, Stacie ^c   Degraffenreid, Michael ^a   Gill, Adrian ^b   Hao, Xiaolin ^a   Hawley, Ronald C ^b   He, Xiao ^a   Jaen, Juan C ^a   Labadie, Sharada S ^b   Labelle, Marc ^a   Lehel, Csaba ^a   Lu, Pu Ping ^a   McIntosh, Joel ^b   Miao, Shichang ^a   Parast, Camran ^a   Shin, Youngsook ^a   Sjogren, Eric B ^b   Smith, Marie Louise ^a   Talamas, Francisco X ^b   Tonn, George ^a   Walker, Keith M ^b   Walker, Nigel P C ^a   Wesche, Holger ^a   Whitehead, Chris ^b   Wright, Matt ^a   Browner, Michelle F ^d   more..

^a AMGEN INC   (United States)

^b Chemistry   (United States)

^c Molecular Biology   (United States)

^d Discovery Technologies   (United States)

Author keywords

IKK ; IKK ; Semicarbazones; Semithiocarbazones

Indexed keywords

IMIDAZOLE; PROTEIN SERINE THREONINE KINASE INHIBITOR; QUINOLINE; THIOSEMICARBAZONE DERIVATIVE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; DRUG POTENCY; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

ANIMALS; DOGS; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; I-KAPPA B KINASE; MALE; MICROSOMES; PROTEIN KINASE INHIBITORS; QUINOLINES; RATS; SEMICARBAZIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78650514545     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.10.126     Document Type: Article

References (37)

1. L.A. Solt, and M.J. May Immunol. Res. 42 2008 3l
2. H. Hacker, and M. Karin Sci. STKE 2006 357
3. J.D. Woronicz, X. Gao, Z. Cao, M. Rothe, and D.V. Goeddel Science 278 1997 866
4. C.H. Regnier, H.Y. Song, X. Gao, D.V. Goeddel, Z. Cao, and M. Rothe Cell 90 1997 373
5. G. Bonizzi, and M. Karin Trends Immunol. 25 2004 280
6. Y. Hu, V. Baud, M. Delhase, P. Zhang, T. Deerinck, M. Ellisman, R. Jounson, and M. Karin Science 284 1999 316
7. M. Karin Cell Res. 18 2008 334
8. V. Pande, and M.J. Ramos Curr. Med. Chem. 12 2005 357
9. M. Karin, and F.R. Greten Nat. Rev. Immunol. 5 2005 749
10. M. Karin, Y. Yamamoto, and Q.M. Wang Nat. Rev. Drug Disc. 3 2004 17
11. J.-L. Luo, H. Kamata, and M. Karin J. Clin. Invest. 115 2005 2625
12. Millennium (Takeda) had entered MLN-0415 a small molecule inhibitor of IKKβ in a phase I study in 2006. The structure has not yet been disclosed.
13. J. Liddle, P. Bamborough, M.D. Barker, S. Campos, R.P.C. Cousins, G.J. Cutler, H. Hobbs, D.S. Holmes, C. Ioannou, G.W. Mellor, M.A. Morse, J.J. Payne, J.M. Pritchard, K.J. Smith, D.T. Tape, C. Whitworth, and R.A. Williamson Bioorg. Med. Chem. Lett. 19 2009 2504
14. Bouaboula, M.; Tonnerre, B. PCT Int. Appl. WO 2009056693.
15. Deng, J.; Kerns, J. K.; Jin, Q.; Lin, G.; Lin, X.; Lindenmuth, M.; Neipp, C.; Nie, H.; Thomas, S. M.; Widdowson, K. L. U.S. Patent Appl. Publ. 2009143372.
16. Fujiwara, H.; Iso, T.; Fujita, K.; Masuda, T.; Higuchi, N.; Hirai, M. PCT Int. Appl. WO 2009075277.
17. Elder, A. M.; Ghosh, S.; Harrison, S. J.; Hepperle, M. E.; Liu, J. F.; Murray, R. S.; Renou, C. C.; Reynolds, D. PCT Int. Appl. WO 2009067233.
18. Enomoto, H.; Kawashima, K.; Kudou, K.; Yamamoto, M.; Murai, M.; Inaba, T.; Ishizaka, N. PCT Int. Appl. WO 2008087933.
19. Moffat, D.; Festus, C.; Davies, S. J.; Charlton, M. H.; Hirst, S. C.; Onions, S. T.; Williams, J. G. PCT Int. Appl. WO 2008053185.
20. Ginn, J. D.; Sorcek, R. J.; Turner, M. R.; Young, E. R. R. U.S. Patent Appl. Publ. 2007293533.
21. Hu, Y.; Sum, F.-W.; Di Grandi, M.; Norton, E. U.S. Patent Appl. Publ. 2007244140 2007.
22. Kim, M. H.; Park, C. H.; Chun, K. W.; Choi, J. W.; Oh, B. K.; Won, R. L.; Jang H.; Kim, K. H.; Kim, S. M. Rep. of Korea 2007040059.
23. Callahan, J. F; Kerns, J. K.; Lin, X. PCT Int. Appl. WO 2007102883.
24. Dahnke, K. R.; Lin, H.-S.; Shih, C.; Wang, Q. M.; Zhang, B.; Richett, M. E. PCT Int. Appl. WO 2007092095.
25. Weber, O.; Ziegelbauer, K.; Seiler, P.; Krahn, T.; Diedrichs, N.; Riedl, B. PCT Int. Appl. WO 200701467.
26. F. Beauliu, C. Ouellett, E.H. Ruediger, M. Belema, Y. Qiu, X. Yang, J. Banville, J.R. Burke, K.R. Gregor, J.F. MacMaster, A. Martel, K.W. McIntyre, M.A. Pattoli, F.C. Zusi, and D. Vyas Bioorg. Med. Chem. Lett. 17 2007 1233
27. A.H. Bingham, R.J. Davenport, L. Gowers, R.L. Knight, C. Lowe, D.A. Owen, D.M. Parry, and W.R. Pitt Bioorg. Med. Chem. Lett. 14 2004 409
28. T. Murato, M. Shimada, S. Sakakibara, T. Yoshino, H. Kadono, T. Masuda, M. Shimazaki, T. Shintani, K. Fuchikami, K. Sakai, H. Inbe, K. Takeshita, T. Niki, M. Umeda, K.B. Bacon, K.B. Ziegelbauer, and T.B. Lowinger Bioorg. Med. Chem. Lett. 13 2003 913
29. A.C. Castro, L.C. Dang, F.G. Soucy, L. Renier, H. Mazdiyasni, M. Hottelet, L. Parent, C. Pien, V. Palombella, and J. Adams Bioorg. Med. Chem. Lett. 13 2003 2419
30. T. Lawrence, M. Bebian, G.Y. Liu, V. Nizet, and M. Karin Nature 434 2005 1138
31. Browner, M. F.; Clark, D. L.; Cushing, T. D.; Hao, X.; Hawley, R. C.; He, X.; Jaen, J. C.; Labadie, S. S.; Smith, M.-L.; Talamas, F. X.; Walker, N. P. C.; Labelle, M. U.S. Patent 6846,834 2005.
32. Browner, M. F.; Clark, D. L.; Cushing, T. D.; Hao, X.; Hawley, R. C.; He, X.; Jaen, J. C.; Labadie, S. S.; Smith, M.-L.; Talamas, F. X.; Walker, N. P. C.; Labelle, M. U.S. Patent 7186,841 2007.
33. Cushing, T. D.; He, X.; Smith, M.-L.; DeGraffenreid, M. R.; Powers, J.; Tomooka, C.; Clark, D. L.; Hao, X.; Jaen, J. C.; Labelle, M.; Walker, N. P. C.; Gill, A. L.; Talamas, F. X.; Labadie, S. U.S. Patent 7176,314 2007.
34. 50s were determined by curve fitting with LSW data analysis software (MDL).
35. NF-kB gel shift assays were carried out as described (Schindler, U.; Baichwal, V. R. Mol. Cell Biol. 1994, 14, 5820). In summary, IL8/ECV304 cells were stimulated with TNF for 1 h in the absence or presence of compounds and NF-kB. DNA binding activity was determined by gel shift experiments from crude nuclear extracts.
36. Human whole blood assay: blood samples in a 96-well microtiter plate were stimulated for 5 h with LPS in the presence or absence of test compounds. Following the incubation period, levels of TNF in the culture supernatants were determined with an ELISA kit (R&D systems).
37. J.A. Zoltewicz, and L.W. Deady Adv. Heterocycl. Chem. 22 1978 71